Galectin Therapeutics (USA) announced on June 30, 2020, the commencement of patient enrolment of the adaptively-designed Phase 2b/3 trial of Belapectin (R-MD-02) in NASH cirrhosis.

For detailed information, see the below URL.

https://investor.galectintherapeutics.com/news-releases/news-release-details/update-galectin-therapeutics-announces-commencement-patient

Belapectin is a galectin-3 inhibitor.  The compound used the STAM^TM mouse model for non-clinical studies, and data showing the improvement of NASH and fibrosis in the STAMTM mouse model was published in PLoS ONE （https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083481).

In the future, we believe that further clinical trial results for Belapectin will provide evidence for the STAM^TM mouse model as a clinically predictive NASH model.